Literature DB >> 32533427

Intravenous regular insulin is an efficient and safe procedure for obtaining high-quality cardiac 18F-FDG PET images: an open-label, single-center, randomized controlled prospective trial.

Yang Chun Chen1,2, Qing Qing Wang3, Yue Hui Wang3, Hui Lin Zhuo4, Ruo Zhu Dai4.   

Abstract

BACKGROUND: An open-label, single-center, randomized controlled prospective trial was performed to assess the efficiency and safety of an insulin loading procedure to obtain high-quality cardiac 18F-FDG PET/CT images for patients with coronary artery disease (CAD).
METHODS: Between November 22, 2018 and August 15, 2019, 60 patients with CAD scheduled for cardiac 18F-FDG PET/CT imaging in our department were randomly allocated in a 1:1 ratio to receive an insulin or standardized glucose loading procedure for cardiac 18F-FDG imaging. The primary outcome was the ratio of interpretable images (high-quality images defined as myocardium-to-liver ratios ≥ 1). The secondary outcome was the patient preparation time (time interval between administration of insulin/glucose and 18F-FDG injection). Hypoglycemia events were recorded.
RESULTS: The ratio of interpretable cardiac PET images in the insulin loading group surpassed the glucose loading group (30/30 vs. 25/30, P = 0.026). Preparation time was 71±2 min shorter for the insulin loading group than for the glucose loading group (P < 0.01). Two and six hypoglycemia cases occurred in the insulin and glucose loading groups, respectively.
CONCLUSION: The insulin loading protocol was a quicker, more efficient, and safer preparation for gaining high-quality cardiac 18F-FDG images.
© 2020. American Society of Nuclear Cardiology.

Entities:  

Keywords:  F18-Fluorodeoxyglucose; cardiac; glucose; insulin; myocytes

Mesh:

Substances:

Year:  2020        PMID: 32533427     DOI: 10.1007/s12350-020-02219-9

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  3 in total

1.  Myocardial glucose utilization and optimization of (18)F-FDG PET imaging in patients with non-insulin-dependent diabetes mellitus, coronary artery disease, and left ventricular dysfunction.

Authors:  G D Vitale; R A deKemp; T D Ruddy; K Williams; R S Beanlands
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

2.  Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.

Authors:  Arend F L Schinkel; Jeroen J Bax; Roelf Valkema; Abdou Elhendy; Ron T van Domburg; Eleni C Vourvouri; Manolis A Bountioukos; Eric P Krenning; Jos R T C Roelandt; Don Poldermans
Journal:  J Nucl Med       Date:  2003-06       Impact factor: 10.057

3.  Value of 12-lead electrocardiogram to predict myocardial scar on FDG PET in heart failure patients.

Authors:  Susanne Markendorf; Dominik C Benz; Michael Messerli; Marvin Grossmann; Andreas A Giannopoulos; Dimitri Patriki; Tobias A Fuchs; Christoph Gräni; Aju P Pazhenkottil; Ronny R Buechel; Philipp A Kaufmann; Oliver Gaemperli
Journal:  J Nucl Cardiol       Date:  2019-08-09       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.